Scientific article
OA Policy
English

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Published inHIV Medicine, vol. 19, no. 2, p. 102-117
Publication date2018
Abstract

There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.

Research groups
Citation (ISO format)
COZZI-LEPRI, A et al. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. In: HIV Medicine, 2018, vol. 19, n° 2, p. 102–117. doi: 10.1111/hiv.12557
Main files (1)
Article (Published version)
Identifiers
Journal ISSN1464-2662
383views
221downloads

Technical informations

Creation06/11/2018 16:19:00
First validation06/11/2018 16:19:00
Update15/03/2023 16:07:03
Status update15/03/2023 16:07:01
Last indexation31/10/2024 13:09:55
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack